Full Press Release Details
Protalix BioTherapeutics to Present at the Piper Jaffray
20th Annual Health Care Conference
CARMIEL, Israel, November 25, 2008 Protalix BioTherapeutics, Inc. (Amex: PLX), announced today
that Dr. David Aviezer, President and CEO, will present at the Piper Jaffray 20th Annual Health
Care Conference on Tuesday, December 2, 2008 at 1:00 PM ET. The conference is being held at the
New York Palace Hotel in New York City.
An audio webcast of the corporate presentation will be available on Protalix s website at
www.protalix.com under the events calendar section.
About Protalix BioTherapeutics
Protalix is a biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical
company focused on the development and commercialization of proprietary recombinant therapeutic
proteins to be expressed through its proprietary plant cell based expression system. Protalix s
ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that
Protalix believes is safe and scalable and will allow for the cost-effective, industrial-scale
production of recombinant therapeutic proteins. Protalix is enrolling and treating patients in its
pivotal phase III clinical trial in Israel, the United States and other locations for its lead
product candidate, prGCD, for its enzyme replacement therapy for Gaucher disease, a lysosomal
storage disorder in humans, and has reached an agreement with the United States Food and Drug
Administration on the final design of the pivotal phase III clinical trial through the FDA s
Special Protocol Assessment (SPA) process. Protalix is also advancing additional recombinant
biopharmaceutical drug development programs.
The Trout Group, LLC
Telephone: 646-378-2927
Email: mstrickler@troutgroup.com